Octagon Capital Advisors LP has disclosed a substantial investment in Precision BioSciences, Inc., holding 5.73% of the company’s common stock. This filing, made on November 3, 2026, is significant as it highlights Octagon's strategic interests in the life sciences sector, particularly in biological products.

Precision BioSciences, based in Durham, North Carolina, specializes in developing innovative therapies using its proprietary ARCUS genome editing technology. The company is classified under the SIC code for Biological Products (No Diagnostic Substances) [2836]. This classification underscores the focus on advanced biological solutions, an area that is increasingly attracting investment from firms like Octagon.

According to the recent filing, Octagon Capital Advisors LP beneficially owns 1,651,497 shares of Precision BioSciences. This includes 430,000 shares directly held, alongside 1,221,497 shares that are issuable upon the exercise of warrants. The filing states, "Each of the foregoing is referred to as a 'Reporting Person' and collectively as the 'Reporting Persons.'" This indicates a structured approach to their investment, involving multiple entities under Octagon's management.

The filing also notes that Octagon is the investment manager for Octagon Investments Master Fund LP, which holds these shares. Ting Jia, the managing member of Octagon, is also listed as a principal beneficial owner. The filing emphasizes that the ownership structure allows Octagon to influence the governance of Precision BioSciences, potentially impacting its strategic decisions.

This investment could have implications for Precision BioSciences as it navigates the competitive landscape of the biological products industry. With Octagon holding a significant stake, there may be increased scrutiny on the company’s performance and strategic direction. The filing indicates that the warrants held by Octagon cannot be exercised if it would result in owning more than 9.99% of the outstanding shares, a limitation referred to as the